EPoS trial has started
After one year with preparations, the European Polyp Surveillance Trial (EPoS) has started patient recruitment. The EPoS study will include 30,000 patients over the next three years. Aim of the study is to find better surveillance intervals for patients with colorectal polyps.
First patient enrolment
The first six patients were randomized at Sørlandet Hospital in Kristiansand, Norway, in May 2015. In June, Oslo University Hospital started to enrol their first patients, and in the first week of August, Poland and Spain started to enrol patients.
The EPoS study is a large multinational project which is financed by multiple sources in the participating countries.
Latest publicationsBurocziova et al. 2019. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death. Dis. 10(11): 818
Eilertsen et al. 2019. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. [Epub ahead of print] Lopes et al. 2019. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Lab. Invest. [Epub ahead of print] Dienstmann et al. 2019. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann. Oncol. [Epub ahead of print] Totland et al. 2019. Regulation of gap junction intercellular communication by connexin ubiquitination: physiological and pathophysiological implications. Cell. Mol. Life Sci. [Epub ahead of print] All publications